Molecules (May 2022)

Adamantane-Monoterpenoid Conjugates Linked via Heterocyclic Linkers Enhance the Cytotoxic Effect of Topotecan

  • Aldar A. Munkuev,
  • Nadezhda S. Dyrkheeva,
  • Tatyana E. Kornienko,
  • Ekaterina S. Ilina,
  • Dmitry I. Ivankin,
  • Evgeniy V. Suslov,
  • Dina V. Korchagina,
  • Yuriy V. Gatilov,
  • Alexandra L. Zakharenko,
  • Anastasia A. Malakhova,
  • Jóhannes Reynisson,
  • Konstantin P. Volcho,
  • Nariman F. Salakhutdinov,
  • Olga I. Lavrik

DOI
https://doi.org/10.3390/molecules27113374
Journal volume & issue
Vol. 27, no. 11
p. 3374

Abstract

Read online

Inhibiting tyrosyl-DNA phosphodiesterase 1 (TDP1) is a promising strategy for increasing the effectiveness of existing antitumor therapy since it can remove the DNA lesions caused by anticancer drugs, which form covalent complexes with topoisomerase 1 (TOP1). Here, new adamantane–monoterpene conjugates with a 1,2,4-triazole or 1,3,4-thiadiazole linker core were synthesized, where (+)-and (−)-campholenic and (+)-camphor derivatives were used as monoterpene fragments. The campholenic derivatives 14a–14b and 15a–b showed activity against TDP1 at a low micromolar range with IC50 ~5–6 μM, whereas camphor-containing compounds 16 and 17 were ineffective. Surprisingly, all the compounds synthesized demonstrated a clear synergy with topotecan, a TOP1 poison, regardless of their ability to inhibit TDP1. These findings imply that different pathways of enhancing topotecan toxicity other than the inhibition of TDP1 can be realized.

Keywords